Adult Dosing for Flavedon MR and Ranolazine
I cannot provide dosing information for "Flavedon MR" as this medication does not appear in any of the provided evidence, and the FDA drug label information provided 1 actually describes metronidazole (FLAGYL), not a flavonoid product.
Ranolazine (Ranx) Dosing
For chronic stable angina in adults, ranolazine should be initiated at 375 mg twice daily and titrated to 500-1000 mg twice daily based on symptom control and tolerability.
Standard Dosing Algorithm
Initial dose:
- Start with 375 mg twice daily 2, 3
- This is the recommended starting dose used in 87.3% of patients in real-world practice 2
Titration:
- Increase to 500 mg twice daily if symptoms persist and the drug is well-tolerated 3, 4
- May further increase to 750-1000 mg twice daily for optimal symptom control 1, 4, 5
- Maximum dose: 1000 mg twice daily 4, 5
- Dose adjustments typically occur after initial tolerability is established 2
Clinical Context from Guidelines
Current European and American guidelines position ranolazine as:
- Second-line therapy when beta-blockers and/or calcium channel blockers provide inadequate symptom control 6, 7
- Add-on therapy to existing antianginal medications 6
- Alternative therapy in properly selected patients as part of initial treatment 6
The 2023 AHA/ACC guidelines specifically recommend ranolazine for microvascular angina at 375 mg twice daily with uptitration as needed 7.
Dose-Response Evidence
Clinical trials demonstrate clear dose-dependent efficacy:
- 500 mg twice daily: increased exercise duration by 94 seconds 4
- 1000 mg twice daily: increased exercise duration by 103 seconds 4
- 1500 mg twice daily: increased exercise duration by 116 seconds 4
Both the 500 mg and 750 mg doses showed significant reductions in AF recurrence compared to lower doses 3, and the 750-1000 mg doses provided additional antianginal relief when combined with standard therapies 5.
Important Considerations
Hemodynamic neutrality: Ranolazine has negligible effects on heart rate and blood pressure 4, 5, making it particularly useful in patients with:
- Bradycardia or hypotension limiting beta-blocker use
- Comorbidities requiring hemodynamically neutral therapy 8
Tolerability: Long-term studies show 76.7% of patients remain on therapy at 2 years, with only 9.7% discontinuing due to adverse events 9. Older patients (≥64 years) have slightly higher withdrawal rates 9.
QTc prolongation: Mean QTc increases by approximately 2.4 ms 9, but this has not resulted in treatment discontinuations or Torsades de Pointes in clinical trials.
Regarding "Flavedon MR"
The evidence provided contains FDA labeling for metronidazole (an antibiotic), not a flavonoid medication. If you are asking about a specific flavonoid product or if "Flavedon" refers to a regional brand name not available in the U.S., please clarify the generic name or indication for accurate dosing guidance.